New data from the QWINT clinical trial may get Eli Lilly closer to bringing a once-weekly insulin injection to the US, ...
The latest clinical trial results from Eli Lilly show the drug manufacturer's once-weekly insulin injection is just as ...
“Glucose-responsive – so-called smart – insulins are regarded as the holy grail of insulin as they would come as close to a ...
Diabetes affects millions of Americans, with 1.4 million new cases diagnosed each year. This chronic condition is one of the ...
An investigational once-weekly insulin was noninferior to a daily option for patients with type 2 diabetes, but proved risky ...
Diabetes affects millions of Americans, with 1.4 million new cases diagnosed each year. This chronic condition is one of the ...
“This long-acting formulation could help address adherence ... Eli Lilly says phase 3 clinical trials indicate that its new weekly insulin injections were as effective as daily injections ...
Diabetes affects millions of Americans, with 1.4 million new cases diagnosed each year ... billion in annual health care ...
Healthcare Asia on MSN12d
Short-acting insulin market to cross $9b by 2030Key drivers include technological advancements and evolving healthcare policies. The global market for short-acting insulin ...
and it now consists of pramlintide 0.6 mg/mL buffered at pH 4.0. The basic pharmacokinetics and pharmacodynamics of a 60-µg dose of the new pramlintide formulation when mixed with insulin remain ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback